News Agency
Men's Weekly

Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

  • Written by PR Newswire
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
  • ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017.
  • IND clearance enables Antengene to initiate the combination portion of the Phase I "ERASER" clinical trial in the United States (U.S.) to evaluate the safety, pharmacokinetics, and preliminary efficacy...

Read more: Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule...

Understanding Your Rights Around Property After Separation

Property division is one of the most significant financial matters that arises when a relationship ends, and it's also one of the most commonly misunderstood. Many people assume that assets are simply divided equally, but the reality under Australian family... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion